课题基金 / 基金详情

Physical Properties and Colloidal Stability of Aluminium Hydroxide Adjuvants (RehydragelTM)

Physical Properties and Colloidal Stability of Aluminium Hydroxide Adjuvants (RehydragelTM)
氢氧化铝佐剂 (ReHydragelTM) 的物理性质和胶体稳定性
批准号:
570656-2021
负责人:
Tam, MichaelMKC
金额:
$2.91万
依托单位:
依托单位国家:
加拿大
项目类别:
Alliance Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
已结题
起止时间:
2022-01-01 至 2023-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
Chemtrade生产一系列高度通用的铝基疫苗佐剂(AVA),可用于广泛的pH值,蛋白质结合类型和其他疫苗要求。AVA生产过程中的工艺参数控制可控制其物理性质,如稳定性、流变性、粒度,这些都会影响其作为疫苗佐剂的功效。拟议的研究将集中于阐明AVA的表面特性对其作为疫苗佐剂的稳定性和效力之间的关系。将被量化的关键性质是纳米颗粒的(a)粒度、(B)zeta电位、(c)形态、(d)流变性和(e)表面组成。我们将开发合成方案,以阐明控制Rehydragel佐剂胶体稳定性的参数。此外,我们将对生产批次的Rehydragel样品进行QA分析,以阐明工艺参数与AVA物理性质之间的关系。 该项目的主要目标是发展对AVA胶体化学的基本理解,并利用这些知识来提高和改善AVA的长期稳定性及其作为疫苗佐剂的功效。此外,我们将培训高素质的人员,以支持更好的AVA的开发和生产,以支持人类和兽医应用对疫苗日益增长的需求。
英文摘要
Chemtrade produces an extensive line of highly versatile aluminum-based Vaccine Adjuvants (AVA) that can be used over a broad range of pH, types of protein binding, and other vaccine requirements. The control of the processing parameters in the production of AVA control their physical properties, such as stability, rheology, particle size, which have an impact on their efficacy as vaccine adjuvants. The proposed research will focus on elucidating the relationship between the surface characteristics of AVA on their stability and efficacy as vaccine adjuvants. The key properties that will be quantified are, (a) particle size, (b) zeta potential, (c) morphology, (d) rheology and (e) surface composition of the nanoparticles. We will develop synthetic protocols to elucidate the parameters that control the colloidal stability of the Rehydragel adjuvants. Additionally, we will conduct QA analyses of the Rehydragel samples from production batches in order to elucidate the relationship between processing parameters and the physical properties of the AVA. The key objective of the project is to develop fundamental understanding on the colloidal chemistry of the AVA, and to use this knowledge to advance and improve the performance of the AVA, in terms of their long-term stability and their efficacy as vaccine adjuvants. Additionally, we will train highly qualified personnels to support the development and production of better AVA to support the growing demands and needs of vaccine in human and veterinary applications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金